Mylan slapped with ‘first-to-file’ lawsuit by Noven and Novartis
Image via Wikipedia
Welcome back to the Medical Technology Blog once again Mylan are under fire from the authorities (see related articles below) please read on…
Mylan is being sued by Noven Pharmaceuticals and Novartis over alleged infringement of the latter’s Vivelle-Dot (oestradiol transdermal system) patch product. Noven filed the lawsuits in the US District Court for the Southern District of New York and the US District Court for the District of Vermont after Mylan submitted an ANDA application in the US for approval to market a generic version of Vivelle-Dot, before the expiration of the product’s patent protection in 2014.
As Noven and Novartis filed the suit within 45 days of hearing about Mylan’s ANDA submissions, the FDA is not allowed to approve the generic product until June 2013 at the latest, or until a district court decides the patent is invalid or the product infringing. However, Mylan believes it is the first to file an ANDA containing Paragraph IV certification for all strengths, and hopes to qualify for 180 days of marketing exclusivity, if approval is granted.
Mylan’s patch, a twice-weekly oestradiol transdermal system, has been submitted for approval for 0.025mg/day, 0.0375mg/day, 0.05mg/day, 0.075mg/day and 0.1mg/day strengths, for the treatment of the symptoms of menopause, the treatment of hypoestrogenism and the prevention of post-menopausal osteoporosis.
IMS Health says that Vivelle-Dot had sales in the US of around US$215 million for the 12 months ended 31st December 2010. Vivelle-Dot, which was launched in 2002, is marketed by Novogyne Pharmaceuticals, a joint venture specifically set up by Noven and Novartis to promote the product. With the prospect of generic competition taking a slice of its revenues, neither Noven nor Novartis are going to give up that easy and have served notice that they will “vigorously defend” their intellectual property rights from infringement.
Thanks to Sophie Bracken for this article, Sophie edits Espicom’s newsletter Drug Delivery Insight.
Related articles
- Orion sues Mylan in U.S. over drug patent (reuters.com)
- UPDATE 1-Mylan settles with Pfizer on generic Caduet (reuters.com)
Espicom Business Intelligence
Tagged with: 180 day • 2011 latest on vivelle dot? • 2011 update on vivelle • 2011 vivelle dot versus generic • are pharmaceuticals medical technologies? • blog about the vivelle patch • buy mylan transdermal • do transderm patches expire • do vivelle patches expire • does transdermal patch expire • estradiol • estradiol .05 mg patch mylan • estradiol (mylam) • estradiol 0.1 mg patch • estradiol 0.1mg/day • estradiol mylan patches • estradiol patch .1 mg mylan • estradiol patch .1mg • estradiol patch 0.05mg by mylan • estradiol patch lawsuit • estradiol patch mylan • estradiol transdermal patch generic • estradiol transdermal patch mylan • Estrogen patch • estrogen patch lawsuits • estrogen patches mylan • FDA • fda approved generic caduet • fda vivelle dot • first to file lawsuits • Food and Drug Administration • generic caduet 180 days • generic caduet fda approve • generic estradiol patch from mylan • generic for vivelle • generic for vivelle dot • generic of vivelle • generic vivelle 2011 • generic vivelle dot • generic vivelle dot patch • generic vivelle patch • Hypoestrogenism list • IMS Health • joint venture novartis • latest news vivelle dot patch • Lawsuit • lawsuit mylan temazepam • Litigation filed in 2011 against Novartis • medical patches Novartis • medical technologist lawsuit • Mylan • mylan a - wiki • Mylan and novartis • mylan anda • mylan ANDA vivelle-dot • mylan doxepin lawsuit • mylan estradiol • mylan estradiol 0.1 mg • mylan estradiol 0.1 mg patch • mylan estradiol 0.1mg/day • mylan estradiol litigation • mylan estradiol paches • mylan estradiol patch • mylan estradiol patch phone number • mylan estradiol transdermal patch availability • mylan estradiool patch • mylan estrogen patch • mylan estrogen patch 0.025 • mylan files for estrogen patch • mylan fire • mylan generic caduet • Mylan generic estradiol patch • Mylan launches generic caduet • MYLAN LAW SUITS • Mylan lawsuit for estrogen patch • mylan lawsuits • mylan novartis • mylan patch wiki • mylan pharma • mylan pharmaceuticals blogs • mylan pharmaceuticals lawsuits • mylan pharmaceuticals wiki • mylan sued • mylan sued by novartis estradiol • mylan verapamil lawsuit • mylan vivelle all 4 patents • mylan vivelle dot • mylan vs. vivelle estrodiol • mylan wiki • Novartis • novartis being sued • Novartis estradiol China • novartis estrogen patches • novartis joint ventures • Novartis lawsuit 2011 • novartis litigation 2011 • novartis noven • novartis Noven joint venture • novartis noven mylan • novartis patch • novartis revenue estradiol sales • novartis transdermal patent expiration • novartis transdermal revenue • novartis versus mylan patent vivelle • novartis vivelle dot • noven and novartis • noven competition • noven fda filings estradiol • noven mylan sdny • noven novartis • noven novartis joint venture vivelle • Noven pharma 2010 US revenue • noven pharma revenues • noven pharmaceuticals and mylan • noven pharmaceuticals financials • noven pharmaceuticals revenue • noven pharmaceuticals revenue in 2010 • noven revenue • noven us sales • paragraph about medical technoloy • paragraph iv certification wiki • paragraph iv transdermal • patent expiration vivelle-dot • patent on vivelle dot • Reuters • reuters medical technology • transdermal patch patent expiration • viadot estradiol patch • villa dot estrogen • vivel dot sales in 2010 • vivella dot going generic • vivelle blog • vivelle dot 0.05 • vivelle dot 2010 fda news • vivelle dot blog • vivelle dot blogs • vivelle dot competition • vivelle dot competitors • vivelle dot expiration • Vivelle dot FDA generic • vivelle dot patent • vivelle dot patent 2014 • vivelle dot patent expiration • vivelle dot patent infringemetn • vivelle dot revenue • vivelle dot revenues • vivelle dot sales • vivelle dot strengths • vivelle dot udates for 2011 • vivelle generic • vivelle going generic • vivelle launch date • vivelle launch united states • vivelle litigation • vivelle patch competitors • vivelle patch expiration • vivelle patent • vivelle vs mylan • vivelle-dot 0.05 mg patch • vivelle-dot 0.05mg patch • vivelle-dot generic • vivelle-dot going generic? • vivelle-dot in China • Vivelle-Dot sued • Vivelle-Dott prospect • vivelledot expiration dates • when was vivelle • when was vivelle-dot launched? • wiki mylan a
Filed under: Company News
Like this post? Subscribe to my RSS feed and get loads more!
Noven filed the lawsuits in the US District Court for the Southern District of New York and the US District Court for the District of Vermont after Mylan submitted an ANDA application in the US for approval to market a generic version of Vivelle-Dot, before the expiration of the product’s patent protection in 2014. Mylan’s patch, a twice-weekly oestradiol transdermal system, has been submitted for approval for 0.025mg/day, 0.0375mg/day, 0.05mg/day, 0.075mg/day and 0.1mg/day strengths, for the treatment of the symptoms of menopause, the treatment of hypoestrogenism and the prevention of post-menopausal osteoporosis. With the prospect of generic competition taking a slice of its revenues, neither Noven nor Novartis are going to give up that easy and have served notice that they will “vigorously defend” their intellectual property rights from infringement.